{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:16:32Z","timestamp":1794107792028,"version":"4.8.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chimeric Antigen Receptor (CAR) T-cell therapy is a highly effective treatment for B-cell malignancies but limited in use due to clinically significant hyperinflammatory toxicities. Understanding the pathophysiologic mechanisms which mediate these toxicities can help identify novel management strategies. Here we report a novel in vitro model of the macrophage-endothelial interface to study the effects of CAR T-cell-induced cytokine storm. Using this model, we demonstrate that macrophage-mediated inflammation is regulated by endothelial cell activity. Furthermore, endothelial inflammation occurs independently of macrophages following exposure to CAR T-cell products and the induced endothelial inflammation potentiates macrophage-mediated inflammatory signaling, leading to a hyperinflammatory environment. While corticosteroids, the current gold standard of care, attenuate the resulting macrophage inflammatory signaling, the endothelial activity remains refractory to this treatment strategy. Utilizing a network model, coupled to in vitro secretion profiling, we identified STAT3 programming as critical in regulating this endothelial behavior. Lastly, we demonstrate how targeting STAT3 activity can abrogate endothelial inflammation and attenuate this otherwise hyperinflammatory environment. Our results demonstrate that endothelial cells play a central role in the pathophysiology of CAR T-cell toxicities and targeting the mechanisms driving the endothelial response can guide future clinical management.<\/jats:p>","DOI":"10.1038\/s41598-023-46114-y","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T15:53:49Z","timestamp":1698854029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["An in vitro model of the macrophage-endothelial interface to characterize CAR T-cell induced cytokine storm"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5172-8881","authenticated-orcid":false,"given":"Robert S.","family":"Rosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan S.","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Schloss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin L.","family":"Yarmush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"issue":"6","key":"46114_CR1","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s11596-019-2118-z","volume":"39","author":"X Yang","year":"2019","unstructured":"Yang, X., Wang, G.-X. & Zhou, J.-F. CAR T cell therapy for hematological malignancies. Curr. Med. Sci. 39(6), 874\u2013882 (2019).","journal-title":"Curr. Med. Sci."},{"key":"46114_CR2","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov."},{"key":"46114_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.retram.2018.03.003","volume":"66","author":"J Gauthier","year":"2018","unstructured":"Gauthier, J. & Turtle, C. J. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr. Res. Transl. Med. 66, 50\u201352. https:\/\/doi.org\/10.1016\/j.retram.2018.03.003 (2018).","journal-title":"Curr. Res. Transl. Med."},{"key":"46114_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/jnen\/nly064","volume":"77","author":"M Torre","year":"2018","unstructured":"Torre, M. et al. Neuropathology of a case with fatal CAR T-cell-associated cerebral edema. J. Neuropathol. Exp. Neurol. 77, 877\u2013882. https:\/\/doi.org\/10.1093\/jnen\/nly064 (2018).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"46114_CR5","doi-asserted-by":"publisher","first-page":"eaaw2127","DOI":"10.1126\/scitranslmed.aaw2127","volume":"11","author":"L Schultz","year":"2019","unstructured":"Schultz, L. & Mackall, C. Driving CAR T cell translation forward. Sci. Trans. Med. 11, eaaw2127 (2019).","journal-title":"Sci. Trans. Med."},{"key":"46114_CR6","first-page":"717","volume":"41","author":"I-Y Jung","year":"2018","unstructured":"Jung, I.-Y. & Lee, J. Unleashing the therapeutic potential of CAR-T cell therapy using gene-editing technologies. Mol. Cells 41, 717 (2018).","journal-title":"Mol. Cells"},{"key":"46114_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","volume":"4","author":"I Hernandez","year":"2018","unstructured":"Hernandez, I., Prasad, V. & Gellad, W. F. Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol. 4, 994\u2013996 (2018).","journal-title":"JAMA Oncol."},{"key":"46114_CR8","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jcyt.2017.04.001","volume":"19","author":"N Singh","year":"2017","unstructured":"Singh, N. et al. Monocyte lineage\u2013derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy 19, 867\u2013880 (2017).","journal-title":"Cytotherapy"},{"key":"46114_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738. https:\/\/doi.org\/10.1038\/s41591-018-0041-7 (2018).","journal-title":"Nat. Med."},{"key":"46114_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"46114_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nri978","volume":"3","author":"S Gordon","year":"2003","unstructured":"Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23\u201335 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"46114_CR12","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/jcmm.16176","volume":"25","author":"J Pan","year":"2021","unstructured":"Pan, J. et al. Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy. J. Cell. Mol. Med. 25, 1089\u20131099 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"46114_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust, J., Taraseviciute, A. & Turtle, C. J. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs 32, 1091\u20131101 (2018).","journal-title":"CNS Drugs"},{"key":"46114_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25502","volume":"86","author":"J Gust","year":"2019","unstructured":"Gust, J. et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann. Neurol. 86, 42\u201354 (2019).","journal-title":"Ann. Neurol."},{"key":"46114_CR15","doi-asserted-by":"crossref","unstructured":"Gustine, J. N. & Jones, D. Immunopathology of hyperinflammation in COVID-19. Am. J. Pathol. (2020).","DOI":"10.1016\/j.ajpath.2020.08.009"},{"key":"46114_CR16","doi-asserted-by":"crossref","unstructured":"Pilotto, A. et al. SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses. Clin. Infect. Dis. (2021).","DOI":"10.1093\/cid\/ciaa1933"},{"key":"46114_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cns.13569","volume":"27","author":"X Huang","year":"2021","unstructured":"Huang, X., Hussain, B. & Chang, J. Peripheral inflammation and blood\u2013brain barrier disruption: effects and mechanisms. CNS Neurosci. Therap. 27, 36\u201347 (2021).","journal-title":"CNS Neurosci. Therap."},{"key":"46114_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust, J., Ponce, R., Liles, W. C., Garden, G. A. & Turtle, C. J. Cytokines in CAR T cell\u2013associated neurotoxicity. Front. Immunol. 11, 577027 (2020).","journal-title":"Front. Immunol."},{"key":"46114_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41409-019-0602-5","volume":"54","author":"CK Chou","year":"2019","unstructured":"Chou, C. K. & Turtle, C. J. Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy. Bone Marrow Trans. 54, 780\u2013784 (2019).","journal-title":"Bone Marrow Trans."},{"key":"46114_CR20","doi-asserted-by":"crossref","unstructured":"Hunter, B. D. & Jacobson, C. A. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. JNCI: J. Natl. Cancer Ins. 111, 646\u2013654 (2019).","DOI":"10.1093\/jnci\/djz017"},{"key":"46114_CR21","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/2159-8290.CD-17-1084","volume":"7","author":"CL Mackall","year":"2017","unstructured":"Mackall, C. L. & Miklos, D. B. CNS endothelial cell activation emerges as a driver of CAR T cell\u2013associated neurotoxicity. Cancer Dis. 7, 1371\u20131373 (2017).","journal-title":"Cancer Dis."},{"key":"46114_CR22","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","volume":"294","author":"M Sachdeva","year":"2019","unstructured":"Sachdeva, M., Duchateau, P., Depil, S., Poirot, L. & Valton, J. Granulocyte\u2013macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J. Biol. Chem. 294, 5430\u20135437 (2019).","journal-title":"J. Biol. Chem."},{"key":"46114_CR23","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/bit.25282","volume":"111","author":"JA Barminko","year":"2014","unstructured":"Barminko, J. A., Nativ, N. I., Schloss, R. & Yarmush, M. L. Fractional factorial design to investigate stromal cell regulation of macrophage plasticity. Biotechnol. Bioeng. 111, 2239\u20132251 (2014).","journal-title":"Biotechnol. Bioeng."},{"key":"46114_CR24","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum, D. C. & June, C. H. Cytokine storm. N. England J. Med. 383, 2255\u20132273 (2020).","journal-title":"N. England J. Med."},{"key":"46114_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1128\/MMBR.05015-11","volume":"76","author":"JR Tisoncik","year":"2012","unstructured":"Tisoncik, J. R. et al. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76, 16\u201332 (2012).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"46114_CR26","unstructured":"Davila, M. L. et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Trans. Med. 6, 224ra225\u2013224ra225 (2014)."},{"key":"46114_CR27","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1203\/01.pdr.0000219120.92049.b3","volume":"59","author":"ZH Aghai","year":"2006","unstructured":"Aghai, Z. H. et al. Dexamethasone suppresses expression of Nuclear Factor-kappaB in the cells of tracheobronchial lavage fluid in premature neonates with respiratory distress. Pediatric Res. 59, 811\u2013815 (2006).","journal-title":"Pediatric Res."},{"key":"46114_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.270.5234.286","volume":"270","author":"N Auphan","year":"1995","unstructured":"Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A. & Karin, M. Immunosuppression by glucocorticoids: inhibition of NF-\u03baB activity through induction of I\u03baB synthesis. Science 270, 286\u2013290 (1995).","journal-title":"Science"},{"key":"46114_CR29","first-page":"697","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner, R. M. et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood, J. Am. Soc. Hematol. 133, 697\u2013709 (2019).","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"46114_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85\u201396 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"46114_CR31","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1089\/ars.2010.3642","volume":"15","author":"ME Widlansky","year":"2011","unstructured":"Widlansky, M. E. & Gutterman, D. D. Regulation of endothelial function by mitochondrial reactive oxygen species. Antioxid. Redox Signal. 15, 1517\u20131530 (2011).","journal-title":"Antioxid. Redox Signal."},{"key":"46114_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2017.05.005","volume":"100","author":"MA Incalza","year":"2018","unstructured":"Incalza, M. A. et al. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vas. Pharmacol. 100, 1\u201319 (2018).","journal-title":"Vas. Pharmacol."},{"key":"46114_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.661838","volume":"15","author":"F Takata","year":"2021","unstructured":"Takata, F., Nakagawa, S., Matsumoto, J. & Dohgu, S. Blood-brain barrier dysfunction amplifies the development of neuroinflammation: understanding of cellular events in brain microvascular endothelial cells for prevention and treatment of BBB dysfunction. Front. Cell. Neurosci. 15, 661838 (2021).","journal-title":"Front. Cell. Neurosci."},{"key":"46114_CR34","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.it.2017.05.002","volume":"38","author":"R Alon","year":"2017","unstructured":"Alon, R. & van Buul, J. D. Leukocyte breaching of endothelial barriers: the actin link. Trends Immunol. 38, 606\u2013615 (2017).","journal-title":"Trends Immunol."},{"key":"46114_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mvr.2008.09.012","volume":"77","author":"N Prasain","year":"2009","unstructured":"Prasain, N. & Stevens, T. The actin cytoskeleton in endothelial cell phenotypes. Microvas. Res. 77, 53\u201363 (2009).","journal-title":"Microvas. Res."},{"key":"46114_CR36","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1152\/jappl.2001.91.4.1487","volume":"91","author":"SM Dudek","year":"2001","unstructured":"Dudek, S. M. & Garcia, J. G. Cytoskeletal regulation of pulmonary vascular permeability. J. Appl. Physiol. 91, 1487\u20131500 (2001).","journal-title":"J. Appl. Physiol."},{"key":"46114_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/10623320109165319","volume":"8","author":"CE Patterson","year":"2001","unstructured":"Patterson, C. E. & Lum, H. Update on pulmonary edema: the role and regulation of endothelial barrier function. Endothelium 8, 75\u2013105 (2001).","journal-title":"Endothelium"},{"key":"46114_CR38","doi-asserted-by":"publisher","first-page":"C589","DOI":"10.1152\/ajpcell.00235.2017","volume":"314","author":"H Alsaffar","year":"2018","unstructured":"Alsaffar, H., Martino, N., Garrett, J. P. & Adam, A. P. Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis. Am. J. Physiol.-Cell Physiol. 314, C589\u2013C602 (2018).","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"46114_CR39","doi-asserted-by":"crossref","unstructured":"Martino, N. et al. Endothelial SOCS3 maintains homeostasis and promotes survival in endotoxemic mice. JCI Insight 6 (2021).","DOI":"10.1172\/jci.insight.147280"},{"key":"46114_CR40","doi-asserted-by":"crossref","unstructured":"Chaves de Souza, J. A. et al. SOCS3 expression correlates with severity of inflammation, expression of proinflammatory cytokines, and activation of STAT3 and p38 MAPK in LPS-induced inflammation in vivo. Med. Inflamm. 2013 (2013).","DOI":"10.1155\/2013\/650812"},{"key":"46114_CR41","doi-asserted-by":"crossref","unstructured":"Seyedhamzeh, M. et al. The potential of JAK\/STAT pathway inhibition as a New Treatment Strategy to Control Cytokine Release Syndrome in COVID-19. (2020).","DOI":"10.26434\/chemrxiv.12951089"},{"key":"46114_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116832","volume":"413","author":"AA Asadi-Pooya","year":"2020","unstructured":"Asadi-Pooya, A. A. & Simani, L. Central nervous system manifestations of COVID-19: a systematic review. J. Neurol. Sci. 413, 116832 (2020).","journal-title":"J. Neurol. Sci."},{"key":"46114_CR43","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s10072-020-04525-z","volume":"41","author":"V Vacchiano","year":"2020","unstructured":"Vacchiano, V. et al. Early neurological manifestations of hospitalized COVID-19 patients. Neurol. Sci. 41, 2029\u20132031 (2020).","journal-title":"Neurol. Sci."},{"key":"46114_CR44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.17116\/jnevro2020120091114","volume":"120","author":"A Kholin","year":"2020","unstructured":"Kholin, A. et al. Features of neurological manifestations of the COVID-19 in children and adults. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova 120, 114\u2013120 (2020).","journal-title":"Zhurnal nevrologii i psikhiatrii imeni SS Korsakova"},{"key":"46114_CR45","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1038\/s41418-020-00633-7","volume":"27","author":"T Matsuyama","year":"2020","unstructured":"Matsuyama, T., Kubli, S. P., Yoshinaga, S. K., Pfeffer, K. & Mak, T. W. An aberrant STAT pathway is central to COVID-19. Cell Death Diff. 27, 3209\u20133225 (2020).","journal-title":"Cell Death Diff."},{"key":"46114_CR46","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s12035-020-02149-0","volume":"58","author":"HS Zangbar","year":"2021","unstructured":"Zangbar, H. S., Gorji, A. & Ghadiri, T. A review on the neurological manifestations of covid-19 infection: a mechanistic view. Mol. Neurobiol. 58, 536\u2013549 (2021).","journal-title":"Mol. Neurobiol."},{"key":"46114_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155404","volume":"138","author":"P Thepmankorn","year":"2021","unstructured":"Thepmankorn, P. et al. Cytokine storm induced by SARS-CoV-2 infection: The spectrum of its neurological manifestations. Cytokine 138, 155404 (2021).","journal-title":"Cytokine"},{"key":"46114_CR48","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.humimm.2015.09.037","volume":"76","author":"Y Yin","year":"2015","unstructured":"Yin, Y., Liu, W. & Dai, Y. SOCS3 and its role in associated diseases. Human Immunol. 76, 775\u2013780 (2015).","journal-title":"Human Immunol."},{"key":"46114_CR49","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson, D. E., O\u2019Keefe, R. A. & Grandis, J. R. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234\u2013248 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"46114_CR50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12031-014-0320-9","volume":"55","author":"Q Xu","year":"2015","unstructured":"Xu, Q. et al. The effects of fludarabine on rat cerebral ischemia. J. Mol. Neurosci. 55, 289\u2013296 (2015).","journal-title":"J. Mol. Neurosci."},{"key":"46114_CR51","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2991\/chi.k.201108.001","volume":"2","author":"A Zahid","year":"2020","unstructured":"Zahid, A., Siegler, E. L. & Kenderian, S. S. CART cell toxicities: new insight into mechanisms and management. Clinical Hematol. Int. 2, 149 (2020).","journal-title":"Clinical Hematol. Int."},{"key":"46114_CR52","unstructured":"Huarte, E. et al. (American Society of Hematology Washington, DC, 2019)."},{"key":"46114_CR53","doi-asserted-by":"crossref","unstructured":"Gu, C. et al. Successful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy. Leukemia & Lymphoma, 1\u20134 (2022).","DOI":"10.1080\/10428194.2022.2148209"},{"key":"46114_CR54","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2022.01.070","volume":"595","author":"N Xu","year":"2022","unstructured":"Xu, N. et al. Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells. Biochem. Biophys. Res. Commun. 595, 54\u201361 (2022).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"46114_CR55","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1182\/blood.V128.22.652.652","volume":"128","author":"SS Kenderian","year":"2016","unstructured":"Kenderian, S. S. et al. Ruxolitinib prevents cytokine release syndrome after CART cell therapy without impairing the anti-tumor effect in a xenograft model. Blood 128, 652 (2016).","journal-title":"Blood"},{"key":"46114_CR56","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1084\/jem.174.6.1517","volume":"174","author":"N Mackman","year":"1991","unstructured":"Mackman, N., Brand, K. & Edgington, T. S. Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. J. Exp. Med. 174, 1517\u20131526 (1991).","journal-title":"J. Exp. Med."},{"key":"46114_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1546-9","volume":"15","author":"M Genin","year":"2015","unstructured":"Genin, M., Clement, F., Fattaccioli, A., Raes, M. & Michiels, C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer 15, 1\u201314 (2015).","journal-title":"BMC Cancer"},{"key":"46114_CR58","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/cyto.a.20952","volume":"77","author":"V Mak\u00f3","year":"2010","unstructured":"Mak\u00f3, V. et al. Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1\u03b2, TNF-\u03b1, and LPS. Cytometry Part A 77, 962\u2013970 (2010).","journal-title":"Cytometry Part A"},{"key":"46114_CR59","doi-asserted-by":"crossref","unstructured":"Chen, Y. et al. Therapeutic potential of TNF\u03b1 and IL1\u03b2 blockade for CRS\/ICANS in CAR-T therapy via ameliorating endothelial activation. Front. Immunol. 1848 (2021).","DOI":"10.3389\/fimmu.2021.623610"},{"key":"46114_CR60","doi-asserted-by":"crossref","unstructured":"Liu, X. et al. Network analysis reveals a distinct axis of macrophage activation in response to conflicting inflammatory cues. bioRxiv, 844464 (2019).","DOI":"10.1101\/844464"},{"key":"46114_CR61","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.4049\/jimmunol.1502513","volume":"198","author":"P Wentker","year":"2017","unstructured":"Wentker, P. et al. An interactive macrophage signal transduction map facilitates comparative analyses of high-throughput data. J. Immunol. 198, 2191\u20132201 (2017).","journal-title":"J. Immunol."},{"key":"46114_CR62","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3389\/fphys.2017.00960","volume":"8","author":"N Weinstein","year":"2017","unstructured":"Weinstein, N., Mendoza, L., Gitler, I. & Klapp, J. A network model to explore the effect of the micro-environment on endothelial cell behavior during angiogenesis. Front. Physiol. 8, 960 (2017).","journal-title":"Front. Physiol."},{"key":"46114_CR63","doi-asserted-by":"publisher","first-page":"5409","DOI":"10.1091\/mbc.e08-05-0477","volume":"19","author":"L Paris","year":"2008","unstructured":"Paris, L. & Bazzoni, G. The protein interaction network of the epithelial junctional complex: a system-level analysis. Mol. Biol. Cell 19, 5409\u20135421 (2008).","journal-title":"Mol. Biol. Cell"},{"key":"46114_CR64","doi-asserted-by":"crossref","unstructured":"Nayak, S. et al. Using a systems pharmacology model of the blood coagulation network to predict the effects of various therapies on biomarkers. CPT: Pharmacomet. Syst. Pharmacol. 4, 396\u2013405 (2015).","DOI":"10.1002\/psp4.50"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46114-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46114-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46114-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T03:03:01Z","timestamp":1698894181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46114-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["46114"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-46114-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]},"assertion":[{"value":"17 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18835"}}